Valerio Pascua, 65 patient colchicine ICU study: 23% lower mortality [p=0.6] and 40% lower ICU admission [p=0.03] https://c19p.org/valeriopascua
copied to clipboard
A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients
et al., PLOS ONE, doi:10.1371/journal.pone.0245025
Retrospective 65 ICU patients in the USA and Honduras, showing shorter ICU stay with combined treatment including colchicine,
LMWH, tocilizumab, dexamethasone, and methylprednisolone.
LMWH, tocilizumab, dexamethasone, and methylprednisolone.
|
risk of death, 22.8% lower, RR 0.77, p = 0.60, treatment 5 of 35 (14.3%), control 12 of 30 (40.0%), NNT 3.9, adjusted per study, odds ratio converted to relative risk, multivariable.
|
|
ICU time, 39.9% lower, relative time 0.60, p = 0.03, treatment 35, control 30, adjusted per study, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Valerio Pascua et al., 1/7/2021, retrospective, multiple countries, multiple regions, peer-reviewed, 19 authors, study period 10 June, 2020 - 6 August, 2020, average treatment delay 6.1 days, this trial uses multiple treatments in the treatment arm (combined with LMWH, tocilizumab, dexamethasone, methylprednisolone) - results of individual treatments may vary.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.